This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kune, G. A. Articles by Watson, L. F. Search for Related Content PubMed PubMed Citation Articles by Kune, G. A. Articles by Watson, L. F.

Colorectal Cancer Risk, Chronic Illnesses, Operations, and Medications: Case Control Results from the Melbourne Colorectal Cancer Study¹

Department of Surgery, University of Melbourne, Repatriation General Hospital, Heidelberg 3081, Victoria, Australia

The associations between colorectal cancer risk and several chronic illnesses, operations, and various medications were examined in 715 colorectal cancer cases and 727 age/sex-matched controls in data derived from a large, comprehensive, population-based study of this cancer conducted in Melbourne, Australia. There was a statistically significant deficit among cases of hypertension, heart disease, stroke, chronic chest disease, and chronic arthritis and a statistically significant excess of "hemorrhoids" among cases, and all of these differences were consistent for both colon and rectal cancer and for both males and females. Although no statistically significant differences were found for other cancers, there were twice as many breast cancers among cases (16) than among controls (8) and also there were 9 uterine cancers among cases and only 2 among controls. There was a statistically significant deficit among cases in the use of aspirin-containing medication and vitamin supplements, and this was consistent for both colon and rectal cancer and for both males and females. There was a statistically significant excess of large bowel polypectomy among cases. The modeling of these significant associations simultaneously in a logistic regression equation indicated that hypertension, heart disease, chronic arthritis, and aspirin use were each independent effects and consistent for both colon and rectal cancer for both males and females and also that these effects were independent of dietary risk factors previously described in the Melbourne study. The possible relevance of these findings towards an understanding of colorectal cancer risk and etiology is discussed.

¹ This part of the Melbourne Colorectal Cancer Study was generously supported by the "Nicholas and Elizabeth Slezak Cancer Research Fund" of the University of Melbourne.

² To whom requests for reprints should be addressed.

Received 5/ 4/87. Revised 10/15/87. Revised 4/11/88. Accepted 4/27/88.

This article has been cited by other articles:

				C.-W. Lee, B. Rickman, A. B. Rogers, S. Muthupalani, S. Takaishi, P. Yang, T. C. Wang, and J. G. Fox Combination of Sulindac and Antimicrobial Eradication of Helicobacter pylori Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice Cancer Res., October 15, 2009; 69(20): 8166 - 8174. [Abstract] [Full Text] [PDF]

				J.-Y. Liou, C.-C. Wu, B.-R. Chen, L. B. Yen, and K. K. Wu Nonsteroidal Anti-Inflammatory Drugs Induced Endothelial Apoptosis by Perturbing Peroxisome Proliferator-Activated Receptor-{delta} Transcriptional Pathway Mol. Pharmacol., November 1, 2008; 74(5): 1399 - 1406. [Abstract] [Full Text] [PDF]

				K. Sapienza, W. Bannister, and R. Balzan Mitochondrial involvement in aspirin-induced apoptosis in yeast Microbiology, September 1, 2008; 154(9): 2740 - 2747. [Abstract] [Full Text] [PDF]

				N. Arber Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1852 - 1857. [Abstract] [Full Text] [PDF]

				A. N. Viswanathan, D. Feskanich, E. S. Schernhammer, and S. E. Hankinson Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer Cancer Res., April 1, 2008; 68(7): 2507 - 2513. [Abstract] [Full Text] [PDF]

				A. E. Prizment, A. R. Folsom, J. R. Cerhan, A. Flood, J. A. Ross, and K. E. Anderson History of Allergy and Reduced Incidence of Colorectal Cancer, Iowa Women's Health Study Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2357 - 2362. [Abstract] [Full Text] [PDF]

				G. Kune Commentary: Aspirin and cancer prevention Int. J. Epidemiol., October 5, 2007; (2007) dym194v1. [Full Text] [PDF]

				R. Logan Commentary: Preventing colorectal cancer with aspirin what next? Int. J. Epidemiol., October 5, 2007; (2007) dym204v1. [Full Text] [PDF]

				E. Flossmann and P. M Rothwell Commentary: Aspirin and colorectal cancer an epidemiological success story Int. J. Epidemiol., October 1, 2007; 36(5): 962 - 965. [Full Text] [PDF]

				D. A Lawlor Quality in epidemiological research: should we be submitting papers before we have the results and submitting more hypothesis-generating research? Int. J. Epidemiol., October 1, 2007; 36(5): 940 - 943. [Full Text] [PDF]

				N. Iwase, T. Higuchi, T. Gonda, H. Kobayashi, H. Uetake, M. Enomoto, and K. Sugihara The Effect of Meloxicam, a Selective COX-2 Inhibitor, on the Microvasculature of Small Metastatic Liver Tumors in Rats Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 673 - 678. [Abstract] [Full Text] [PDF]

				L. Ellison-Loschmann, Y. Benavente, J. Douwes, E. Buendia, R. Font, T. Alvaro, M. Kogevinas, and S. de Sanjose Immunoglobulin E Levels and Risk of Lymphoma in a Case-Control Study in Spain Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1492 - 1498. [Abstract] [Full Text] [PDF]

				U.S. Preventive Services Task Force* Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, March 6, 2007; 146(5): 361 - 364. [Abstract] [Full Text] [PDF]

				C. Dube, A. Rostom, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 365 - 375. [Abstract] [Full Text] [PDF]

				A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF]

				J. H. Hayes, K. E. Anderson, and A. R. Folsom Association between Nonsteroidal Anti-inflammatory Drug Use and the Incidence of Lung Cancer in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2226 - 2231. [Abstract] [Full Text] [PDF]

				A. Mahipal, K. E. Anderson, P. J. Limburg, and A. R. Folsom Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1785 - 1790. [Abstract] [Full Text] [PDF]

				B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats. Cancer Res., April 15, 2006; 66(8): 4542 - 4546. [Abstract] [Full Text] [PDF]

				H A Patsos, D J Hicks, R R H Dobson, A Greenhough, N Woodman, J D Lane, A C Williams, and C Paraskeva The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 Gut, December 1, 2005; 54(12): 1741 - 1750. [Abstract] [Full Text] [PDF]

				S. C. Larsson, N. Orsini, and A. Wolk Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis J Natl Cancer Inst, November 16, 2005; 97(22): 1679 - 1687. [Abstract] [Full Text] [PDF]

				L. B. Sansbury, R. C. Millikan, J. C. Schroeder, P. G. Moorman, K. E. North, and R. S. Sandler Use of Nonsteroidal Antiinflammatory Drugs and Risk of Colon Cancer in a Population-based, Case-Control Study of African Americans and Whites Am. J. Epidemiol., September 15, 2005; 162(6): 548 - 558. [Abstract] [Full Text] [PDF]

				A. T. Chan, E. L. Giovannucci, J. A. Meyerhardt, E. S. Schernhammer, G. C. Curhan, and C. S. Fuchs Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer JAMA, August 24, 2005; 294(8): 914 - 923. [Abstract] [Full Text] [PDF]

				A. Goel, C. Gasche, and C. R. Boland Chemoprevention Goes Gourmet: Different Flavors of NO-Aspirin Mol. Interv., August 1, 2005; 5(4): 207 - 210. [Abstract] [Full Text] [PDF]

				B. Rigas and K. Kashfi Cancer Prevention: A New Era beyond Cyclooxygenase-2 J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]

				M. Lindblad, J. Lagergren, and L. A. Garcia Rodriguez Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 444 - 450. [Abstract] [Full Text] [PDF]

				N. Tsuneoka, Y. Tajima, A. Kitazato, K. Fukuda, T. Kitajima, T. Kuroki, S. Onizuka, and T. Kanematsu Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters Carcinogenesis, February 1, 2005; 26(2): 465 - 469. [Abstract] [Full Text] [PDF]

				T. J. Jang, H. J. Kang, J. R. Kim, and C. H. Yang Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis Carcinogenesis, October 1, 2004; 25(10): 1853 - 1858. [Abstract] [Full Text] [PDF]

				N. R. Sivak-Sears, J. A. Schwartzbaum, R. Miike, M. Moghadassi, and M. Wrensch Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme Am. J. Epidemiol., June 15, 2004; 159(12): 1131 - 1139. [Abstract] [Full Text] [PDF]

				S. S. Coughlin, E. E. Calle, L. R. Teras, J. Petrelli, and M. J. Thun Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults Am. J. Epidemiol., June 15, 2004; 159(12): 1160 - 1167. [Abstract] [Full Text] [PDF]

				K.-T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, and N. Day Preliminary Communication: Glycated Hemoglobin, Diabetes, and Incident Colorectal Cancer in Men and Women: A Prospective Analysis from the European Prospective Investigation into Cancer-Norfolk Study Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 915 - 919. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918. [Full Text] [PDF]

				V. Quidville, N. Segond, E. Pidoux, R. Cohen, A. Jullienne, and S. Lausson Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase Endocrinology, May 1, 2004; 145(5): 2561 - 2571. [Abstract] [Full Text] [PDF]

				J. Cullen, M. D. Schwartz, W. F. Lawrence, J. V. Selby, and J. S. Mandelblatt Short-Term Impact of Cancer Prevention and Screening Activities on Quality of Life J. Clin. Oncol., March 1, 2004; 22(5): 943 - 952. [Abstract] [Full Text] [PDF]

				E. T. Chang, T. Zheng, E. G. Weir, M. Borowitz, R. B. Mann, D. Spiegelman, and N. E. Mueller Aspirin and the Risk of Hodgkin's Lymphoma in a Population-Based Case-Control Study J Natl Cancer Inst, February 18, 2004; 96(4): 305 - 315. [Abstract] [Full Text] [PDF]

				R. S. Sandler Aspirin Prevention of Colorectal Cancer: More or Less? Ann Intern Med, February 3, 2004; 140(3): 224 - 225. [Full Text] [PDF]

				G. D. Smith and S. Ebrahim Mendelian randomization: prospects, potentials, and limitations Int. J. Epidemiol., February 1, 2004; 33(1): 30 - 42. [Full Text] [PDF]

				J. M Herendeen and C. Lindley Use of NSAIDs for the Chemoprevention of Colorectal Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674. [Abstract] [Full Text] [PDF]

				R. S. Sandler, S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, J. M. Pipas, D. D. Karp, C. L. Loprinzi, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer N. Engl. J. Med., March 6, 2003; 348(10): 883 - 890. [Abstract] [Full Text] [PDF]

				P. Boyle and M. E. Leon Epidemiology of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 1 - 25. [Abstract] [Full Text] [PDF]

				H. J. Lin, K. M. Lakkides, T. O. Keku, S. T. Reddy, A. D. Louie, I. H. Kau, H. Zhou, J. S. Y. Gim, H. L. Ma, C. F. Matthies, et al. Prostaglandin H Synthase 2 Variant (Val511Ala) in African Americans May Reduce the Risk for Colorectal Neoplasia Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1305 - 1315. [Abstract] [Full Text] [PDF]

				P. M. Brauer, G. E. McKeown-Eyssen, V. Jazmaji, A. G. Logan, D. F. Andrews, D. Jenkins, N. Marcon, F. Saibil, L. Cohen, H. Stern, et al. Familial Aggregation of Diabetes and Hypertension in a Case-Control Study of Colorectal Neoplasia Am. J. Epidemiol., October 15, 2002; 156(8): 702 - 713. [Abstract] [Full Text] [PDF]

				M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]

				U. Ladabaum, C. L. Chopra, G. Huang, J. M. Scheiman, M. E. Chernew, and A. M. Fendrick Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: A Cost-Effectiveness Analysis Ann Intern Med, November 6, 2001; 135(9): 769 - 781. [Abstract] [Full Text] [PDF]

				T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations Cancer Res., June 1, 2001; 61(11): 4375 - 4381. [Abstract] [Full Text] [PDF]

				K. Krishnan, M. T. Ruffin, D. Normolle, I. Shureiqi, K. Burney, J. Bailey, M. Peters-Golden, C. L. Rock, C. R. Boland, and D. E. Brenner Colonic Mucosal Prostaglandin E2 and Cyclooxygenase Expression before and after Low Aspirin Doses in Subjects at High Risk or at Normal Risk for Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 447 - 453. [Abstract] [Full Text]

				W A Brown, S A Skinner, C Malcontenti-Wilson, D Vogiagis, and P E O'Brien Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation Gut, May 1, 2001; 48(5): 660 - 666. [Abstract] [Full Text] [PDF]

				M. D. Boudreau, K. H. Sohn, S. H. Rhee, S. W. Lee, J. D. Hunt, and D. H. Hwang Suppression of Tumor Cell Growth Both in Nude Mice and in Culture by n-3 Polyunsaturated Fatty Acids: Mediation through Cyclooxygenase-independent Pathways Cancer Res., February 1, 2001; 61(4): 1386 - 1391. [Abstract] [Full Text]

				R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]

				M. T. Taylor, K. R. Lawson, N. A. Ignatenko, S. E. Marek, D. E. Stringer, B. A. Skovan, and E. W. Gerner Sulindac Sulfone Inhibits K-ras-dependent Cyclooxygenase-2 Expression in Human Colon Cancer Cells Cancer Res., December 1, 2000; 60(23): 6607 - 6610. [Abstract] [Full Text]

				S. N. Agoff, T. A. Brentnall, D. A. Crispin, S. L. Taylor, S. Raaka, R. C. Haggitt, M. W. Reed, I. A. Afonina, P. S. Rabinovitch, A. C. Stevens, et al. The Role of Cyclooxygenase 2 in Ulcerative Colitis-Associated Neoplasia Am. J. Pathol., September 1, 2000; 157(3): 737 - 745. [Abstract] [Full Text] [PDF]

				G. Steinbach, P. M. Lynch, R. K.S. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis N. Engl. J. Med., June 29, 2000; 342(26): 1946 - 1952. [Abstract] [Full Text] [PDF]

				J. P. Plastaras, F. P. Guengerich, D. W. Nebert, and L. J. Marnett Xenobiotic-metabolizing Cytochromes P450 Convert Prostaglandin Endoperoxide to Hydroxyheptadecatrienoic Acid and the Mutagen, Malondialdehyde J. Biol. Chem., April 14, 2000; 275(16): 11784 - 11790. [Abstract] [Full Text] [PDF]

				H-H. S. Chow, D. L. Earnest, D. Clark, N. Mason-Liddil, C. B. Kramer, J. G. Einspahr, J. M. Guillen-Rodriguez, D. J. Roe, W. Malone, J. A. Crowell, et al. Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 351 - 356. [Abstract] [Full Text]

				R. ZEIDLER, M. CSANADY, O. GIRES, S. LANG, B. SCHMITT, and B. WOLLENBERG Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1 FASEB J, April 1, 2000; 14(5): 661 - 668. [Abstract] [Full Text]

				B. S. Reddy Novel Approaches to the Prevention of Colon Cancer by Nutritional Manipulation and Chemoprevention Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 239 - 247. [Abstract] [Full Text]

				H. Y. Lim, H. J. Joo, J. H. Choi, J. W. Yi, M. S. Yang, D. Y. Cho, H. S. Kim, D. K. Nam, K. B. Lee, and H. C. Kim Increased Expression of Cyclooxygenase-2 Protein in Human Gastric Carcinoma Clin. Cancer Res., February 1, 2000; 6(2): 519 - 525. [Abstract] [Full Text]

				K. M. Sheehan, K. Sheahan, D. P. O'Donoghue, F. MacSweeney, R. M. Conroy, D. J. Fitzgerald, and F. E. Murray The Relationship Between Cyclooxygenase-2 Expression and Colorectal Cancer JAMA, October 6, 1999; 282(13): 1254 - 1257. [Abstract] [Full Text] [PDF]

				L. Dreyer and J. H. Olsen Risk for Non-smoking-related Cancer in Atherosclerotic Patients Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 915 - 918. [Abstract] [Full Text]

				F. P. Li and A. S. Whittemore Genetically Tailored Preventive Strategies: an Effective Plan for the Twenty-first Century? Cancer Epidemiol. Biomarkers Prev., August 1, 1999; 8(8): 649 - 658. [Abstract] [Full Text]

				R. E. Schoen, C. M. Tangen, L. H. Kuller, G. L. Burke, M. Cushman, R. P. Tracy, A. Dobs, and P. J. Savage Increased Blood Glucose and Insulin, Body Size, and Incident Colorectal Cancer J Natl Cancer Inst, July 7, 1999; 91(13): 1147 - 1154. [Abstract] [Full Text] [PDF]

				J. D. Potter Colorectal Cancer: Molecules and Populations J Natl Cancer Inst, June 2, 1999; 91(11): 916 - 932. [Abstract] [Full Text] [PDF]

				H. Achiwa, Y. Yatabe, T. Hida, T. Kuroishi, K.-i. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi, and T. Takahashir Prognostic Significance of Elevated Cyclooxygenase 2 Expression in Primary, Resected Lung Adenocarcinomas Clin. Cancer Res., May 1, 1999; 5(5): 1001 - 1005. [Abstract] [Full Text] [PDF]

				F. B. Hu, J. E. Manson, S. Liu, D. Hunter, G. A. Colditz, K. B. Michels, F. E. Speizer, and E. Giovannucci Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women J Natl Cancer Inst, March 17, 1999; 91(6): 542 - 547. [Abstract] [Full Text] [PDF]

				W. Smalley, W. A. Ray, J. Daugherty, and M. R. Griffin Use of Nonsteroidal Anti-inflammatory Drugs and Incidence of Colorectal Cancer: A Population-Based Study Arch Intern Med, January 25, 1999; 159(2): 161 - 166. [Abstract] [Full Text] [PDF]

				M. Hejna, M. Raderer, and C. C. Zielinski Inhibition of Metastases by Anticoagulants J Natl Cancer Inst, January 6, 1999; 91(1): 22 - 36. [Abstract] [Full Text] [PDF]

				T. Takayama, S. Katsuki, Y. Takahashi, M. Ohi, S. Nojiri, S. Sakamaki, J. Kato, K. Kogawa, H. Miyake, and Y. Niitsu Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer N. Engl. J. Med., October 29, 1998; 339(18): 1277 - 1284. [Abstract] [Full Text] [PDF]

				M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]

				G. S. Baldwin, V. J. Murphy, Z. Yang, and T. Hashimoto Binding of Nonsteroidal Antiinflammatory Drugs to the alpha -Subunit of the Trifunctional Protein of Long Chain Fatty Acid Oxidation J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1110 - 1114. [Abstract] [Full Text]

				E. Giovannucci, K. M. Egan, D. J. Hunter, M. J. Stampfer, G. A. Colditz, W. C. Willett, and F. E. Speizer Aspirin and the Risk of Colorectal Cancer in Women N. Engl. J. Med., September 7, 1995; 333(10): 609 - 614. [Abstract] [Full Text] [PDF]

				M. Frisch, J. H. Olsen, A. Bautz, and M. Melbye Benign Anal Lesions and the Risk of Anal Cancer N. Engl. J. Med., August 4, 1994; 331(5): 300 - 302. [Abstract] [Full Text]

				D. M. Waterhouse and D. Brenner Aspirin, NSAIDs, and Risk Reduction of Colorectal Cancer: The Problem Is Translation Arch Intern Med, February 28, 1994; 154(4): 366 - 368. [Abstract] [PDF]

				I. I. Peleg, H. T. Maibach, S. H. Brown, and C. M. Wilcox Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer Arch Intern Med, February 28, 1994; 154(4): 394 - 400. [Abstract] [PDF]